A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIIa Clinical Study Evaluating PEGylated Loxenatide Injection PEX168 in Monotherapy of Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2017
At a glance
- Drugs PEG loxenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 21 Jan 2017 Planned End Date changed from 1 Mar 2016 to 1 Feb 2017.
- 25 Jan 2016 Planned End Date changed from 1 Jan 2016 to 1 Mar 2016 as per ClinicalTrials.gov record.